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Abstract: In our society today, pain has become a main source of strain on most individuals. It
is crucial to develop novel treatments against pain while focusing on decreasing their adverse
effects. Throughout the extent of development for new pain therapies, the nociceptin/orphanin FQ
receptor (NOP receptor) has appeared to be an encouraging focal point. Concentrating on NOP
receptor to treat chronic pain with limited range of unwanted effects serves as a suitable alternative
to prototypical opioid morphine that could potentially lead to life-threatening effects caused by
respiratory depression in overdose, as well as generate abuse and addiction. In addition to these
harmful effects, the uprising opioid epidemic is responsible for becoming one of the most disastrous
public health issues in the US. In this article, the contributing molecular and cellular structure in
controlling the cellular trafficking of NOP receptor and studies that support the role of NOP receptor
and its ligands in pain management are reviewed.
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1. Introduction
Persistent pain affects more than 30% of North America’s population throughout their
life and it attributes to substantial expense in the US with annual costs ranging between $560
and $635 billion, which is larger than the cost of the nation’s priority health conditions [1].
This main socio-economic issue is expected to have a two-fold increase within the next
10 years especially in the elderly, as reported by the 2010 Medical Expenditure Panel Survey
(MEPS). Despite the life- threatening effect caused by respiratory depression in overdose
and the potential of high abuse, opioid analgesics stand as the conventional choice of
treatment for moderate to severe pain [2–6]. As a result of misuse and extensive diversion,
the use of opioids has become a leading crisis in the US, which was declared by the United
States Department of Health and Human Service (HHS) in 2017 [7,8]. According to the
Centers for Disease Control and Prevention (CDC), a significant increase in overdoserelated deaths occurred in 2020 in which the involvement of synthetic opioids was over
60% [9]. For this reason, several research institutes have made it a priority to develop
safe, effective, and non-addictive therapeutics for chronic pain management and address
opioid-use disorders with innovative medications, to save lives and encourage recovery.
Opioids exert their effect via opioid receptors, a member of a large superfamily of
seven-transmembrane-spanning (7TM) G-protein-coupled receptors (GPCRs), mu (MOP
receptor), kappa (KOP receptor), delta (DOP receptor), and nociceptin (NOP receptor) [10].
Since NOP receptors are distributed in various regions (dorsal root ganglia (DRG), spinal
dorsal horn (SDH), and brain) that are involved in pain transmission, NOP receptor ligands
are under investigation primarily as an alternative for MOP receptor opioid analgesic
in addition to their anxiolysis and antidepressant-like effect [11–13]. However, the NOP
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receptor was considered a controversial drug target for analgesics because of its unique
pharmacological effects in pain modulation (antinociceptive vs. nociceptive effects) in the
earlier phases of discovering nociceptin [14–19]. Currently, the NOP receptor has become a
main focus as a promising target for analgesics as NOP receptor ligands have reported to
show antinociceptive effects in non-human primates regardless of their administered doses
and administration routes (spinal or supraspinal).
Moreover, the bifunctional and multifunctional NOP/opioid receptor agonists have recently displayed potent antinociceptive activity with favorable side effect profiles. Among
these agonists, cebranopadol represents a promising therapeutic candidate for pain, according to the results of its clinical trials. In this article, the current literature for NOP receptor’s
crystal structure, distribution, signaling pathway, and the rational design of NOP receptor
ligands with various pharmacological profiles as a promising alternative for conventional
opioid analgesic is reviewed to assess its therapeutic potential as analgesics.
2. Structure of NOP Receptor
In the mid 1990s, the human cDNA clone that encodes the NOP receptor was first
isolated from the human and mouse brainstem and was then identified in several murine
genomes including rat, pig, and guinea pig [20–25]. It was previously known as “orphanin
FQ”, “nociceptin,”, or “ORL-1” for opioid receptor-like 1 receptor, due to the lack of its
endogenous peptide ligand in the binding assays; however, nociceptin or orphanin FQ
(N/OFQ) that closely resemble dynorphin A, a selective KOP receptor endogenous peptide,
was characterized a year later by applying reverse pharmacology as the endogenous
neuropeptide for NOP receptor [14,15]. This endogenous neuropeptide has 17 amino
acids, Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln, which
have quite unique features. The Phe-Gly-Gly-Phe amino terminal is noticeably comparable
to the Tyr-Gly-Gly-Phe that is conserved in other classical opioid peptides [26,27]. Moreover,
the number of Lys and Arg residues that are found in N/OFQ are similar to dynorphin A.
Along with this resemblance, the gene structure of opioid peptide genes (preprodynorphin
and preproenkephalin) and nociceptin precursor gene are also similar [27,28]. Multiple
conserved amino acid residues and motifs specifically in the transmembrane helices and
the intracellular loops have been identified by comparing the cDNA-derived amino acid
sequence of the NOP receptor protein with that of other opioid receptors, indicating that
NOP receptor belongs to GPCR Class A (rhodopsin-like) receptors, as the fourth and last
characterized opioid receptor [29]. Consequently, the IUPHAR nomenclature defined this
receptor and its peptide which are currently named NOP receptor and N/OFQ [30].
To date, three crystal structures of human NOP receptor have been solved with three
piperidine-based antagonists (Banyn Compound-24 (C24), SB-612111, and Compound-35
(C-35)) at a resolution of 3 Å [31,32]. These crystal structures provide a perspective into
the atomic details of the molecular structure of the NOP receptor and support previous
homology models developed to further understand the functional mechanism of NOP
receptor. In all three structures, the protonated nitrogen of the piperidine interacts with
the D1303.32 (superscripts indicate the Ballesteros Weinstein TM helix residue numbering)
residue in NOP receptor which leads to the formation of a salt bridge, implying the high
affinity for these ligands. Consistent with NOP receptor crystal structure in its inactive state,
the previous homology models of NOP receptor in complex with N/OFQ further support
that the N-terminal amino groups of an endogenous neuropeptide agonist, N/OFQ, interact
with D1303.32 [33–35]. This indicates the important role of this residue which is conserved
in other canonical opioid receptors on the binding of NOP receptor ligands. Moreover, the
replacement of D1303.32 into alanine or asparagine in the mutagenesis studies abolished
N/OFQ binding, emphasizing the negative charge essentiality at this location [32].
Computer aided molecular docking studies of the selective NOP receptor agonist Ro
64-6198 into the first active state NOP receptor homology model, have also indicated signs
for the mentioned NOP receptor selectivity enhancing of interactivity [34]. In this model,
the amide hydrogen in Ro 64-6198 directly interacts with T3057.39 to form a hydrogen
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bond that takes place at the extracellular end of the orthosteric binding site, while the
phenalenyl ring of Ro 64-6198 and the hydrophobic V2796.51 residue interact together inside
the binding site.
Despite these studies that have highlighted the key residues and structures that are
involved with ligand binding, receptor activation, and signaling, the determination of
NOP receptor in its active state is required to illuminate the conformational changes in
receptor’s architecture.
3. The Distribution and Signaling Pathway of NOP Receptor
Several techniques and animal model including in situ hybridization, immunohistochemistry, autoradiography, RT-PCR, knock-in mice with a fluorescent-tagged NOP receptor (NOP receptor-eGFP) in place of the native NOP receptor, and [35 S]-GTPγS assay were
employed to reveal the tissue distribution of NOP receptor. It is widely expressed in the
human and other animal species both in the central and peripheral nervous systems [12,36].
Peripherally, the human immune cells (lymphocytic B and T-cell lines, monocytic cell lines,
and circulating lymphocytes and monocytes) express NOP receptor mRNA [37]. Centrally,
the NOP receptor mRNA is detected in the cortical areas, hypothalamus, mammillary
bodies, the substantia nigra, thalamus nuclei, limbic structures (the hippocampus and
amygdala), brainstem (colliculi, the ventral tegmental area, the locus coeruleus), and the
pituitary gland [37,38].
Because NOP receptor activation modulates several physiological functions and pharmacological roles including, but not limited to, pain sensation, mood, learning, memory,
cardiovascular control, and immune response [39], it is important to understand its signaling pathways and subsequent trafficking events. NOP receptor has shown a high sequence
identity and homology in the TM helices and intracellular loops with other classical opioid
receptors (DOP receptor, MOP receptor, and KOP receptor) which couple to inhibitory G
proteins, suggesting a similar activation mechanism upon ligand binding. This binding
triggers the heterotrimeric dissociation of Gαβγ subunits following the replacement of
guanosine diphosphate (GDP) by guanosine triphosphate (GTP) at Gα subunit and subsequently induces multiple intracellular signaling pathways [40,41]. The dissociated Gα
subunit suppresses adenyl cyclase and cAMP production, while Gβγ subunits directly couple with different ion channels such as Ca2+ and Kir3 [42–44]. NOP receptor also regulates
the voltage-dependent Ca2+ channels by modulating Rho-associated coiled-coil-containing
protein kinase (ROCK) and LIM domain kinase (LIMK) [45]. Like canonical opioid receptor,
the suppression of pre and postsynaptic Ca2+ influx, the activation of G protein gated
inward rectifying potassium (GIRKs) conductance, as well as the inhibition of various ions
channels such as Na+ channel resulted in cellular hyperpolarization and attenuation of
neuronal excitability and nociceptive stimuli transmission, thus producing antinociceptive
effects [46]. In addition to ion channels, the activation of NOP receptors also modulates
all three mitogen-activated protein kinase (MAPK). MAPK activity thereby regulates cell
proliferation, progression, and differentiation (ERK1/ERK2), as well as the response to
cellular stressors (p38 and JNK1/JNK2/JNK3) [47,48]. Moreover, the neurotransmitter
release of serotonin, noradrenaline and glutamate, as well as the phospholipase (PLC) A2
and C signaling, are induced by NOP receptor activation [49–52].
Within minutes of NOP receptor activation, the uncoupling of NOP receptor to G
protein is facilitated by a desensitization process, a feedback mechanism to control the
receptor overstimulation during acute and chronic exposure to the ligand [53]. This process
is regulated by various kinases such as GPCR kinases (GRKs) that mediate the phosphorylation, and the arrestin ligation to the C-terminus of the opioid receptor. Besides GRKs,
second messenger-dependent protein kinases including protein kinase A (PKA), protein kinase C (PKC), and calcium/calmodulin-dependent protein kinase II have also been shown
to phosphorylate and desensitize the NOP receptor [54,55]. The receptor desensitization
is suppressed through the inhibition of mitogen activated protein dependent kinase that
could interfere with the arrestin recruitment. After the GRK/arrestin recruitment, the
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NOP receptor is translocated into the intracellular compartment through clathrin-mediated
endocytosis into which the receptor is recycled and re-sensitized to restore the receptor
function back again.
4. Ligands of NOP Receptor
Analgesia is one of the potential clinical indications of NOP receptor due to its wide
distribution in the nervous system (central and peripheral) which are involved in the pain
processing pathways. In this review, NOP receptor ligands including N/OFQ-related
peptides, nonpeptidic, and bifunctional compounds with different pharmacological profiles
(full agonist, partial agonist, and antagonist) that represent viable drug target for pain are
spotlighted. Initially, intrathecally (i.t) administered N/OFQ produces dose-dependent
analgesia in the tail flick assay and flinching behavior in the formalin test without causing sedation as well as promotes antinociceptive effect of morphine in both rats and
monkey [16–19]. Whereas opposite effects like hyperalgesia and a decrease in locomotor
activity are produced as a result of the intracerebroventricular (i.c.v) N/OFQ administration in the hot plate test and the tail flick test in mice [14,15]. The unexpected action
of i.c.v. N/OFQ administration resulted from both the anti-opioid activity (antagonizing
MOP receptor, DOP receptor, and KOP receptor antinociception activity) via NOP receptor
stimulation in the periaqueductal gray (PAG) neurons and the reversal of opioid induced
analgesia of N/OFQ opposed to the nociceptive activity as proposed previously [56–58].
These findings indicate the dual actions of N/OFQ that mainly depend on the administered
dose, pain models (chronic or acute), examined species, and the route of administration
as illustrated in Figure 1. The reason behind this discrepancy across species is not known
yet; however, some studies (reviewed in [29,59]) suggest that the difference in neuronal
circuitry of pain between different species could be the reason for NOP receptor system
having opposite effects in pain processing. Furthermore, the effectiveness of NOP receptor
agonists in addressing chronic pain (over acute pain), can be explained by the varying
levels of NOP receptor mRNA and NFQ peptide induced by chronic inflammation.

Figure 1. N/OFQ effect in rodent and non-human primates on pain response. (A) Supraspinal
administration of N/OFQ produces hyperalgesia and blocks morphine-induced analgesia in rodent,
whereas the opposite effect of analgesia and the promotion of an antinociceptive effect are produced
in non-human primates. (B) Spinal administration of N/OFQ produces dose-dependent analgesia
in both rodent (nanomoles and higher doses) and non-human primates (nanomoles and ultra-low
doses) as well as promotes an antinociceptive effect of morphine, while ultra-low doses of N/OFQ
induce hyperalgesia in rodent.
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In this section, the relevant pharmacological features of NOP receptor ligands including peptide, nonpeptide, and bifunctional and mixed NOP receptor compounds are
explored with a focus on their role in modulating pain to further comprehend the nature of
the N/OFQ–NOP receptor system within these processes.
4.1. Peptide Ligands Related to N/OFQ Targeting Pain
Earlier systematic SAR studies revealed that both truncation and amidation of N/OFQ
are required to sustain the biological activity of N/OFQ and avoid the N-terminus degradation by proteases, respectively [60]. As a result, N/OFQ(1-13)-NH2, which is the shortest
peptide sequence that maintains the potency, efficacy, and affinity as N/OFQ, has been
used as a template to design a new series of N/OFQ analogues. In the frame of SAR
studies, several peptides with distinct pharmacological activity have been identified such
as [Phe1Ψ(CH2-NH)Gly2]N/OFQ(1-13)NH2, UFP-101, and [Nphe1]N/OFQ(1-13)NH2
(NOP receptor antagonists), UFP-112 (highly potent NOP receptor agonist), and UFP-113
(partial NOP receptor agonist) [61–65]. The peptides that have antinociceptive activity are
summarized in Table 1 and described below.
Table 1. The peptides that have antinociceptive activity are summarized.
In Vitro Human NOP Receptor
Name/Structure

[Nphe1 ]N/OFQ(113)NH2

[Nphe1 , Arg14 ,
Lys15 ]N/OFQ-NH2
(UFP-101)

[(pF)Phe4 Aib7 Arg14 Lys15 ]N/OFQNH2
(UFP-112)

Category

Selective
NOP receptor
antagonist

Selective
NOP receptor
antagonist

Selective
NOP receptor
agonist

Receptor
Binding
pKi

8.39

10.24

10.55

[35 S]GTPγS
pKB /pA2

7.33

8.85

10.55

In Vivo

Ca+2
Administration
Mobilization Route/Dose/Species
pKB /pA2

6.29

7.66

9.05

Ref
Effect

(30 nmol)
i.c.v.
mice

Analgesia
Promote
morphineinduced
analgesia.

[61]

(10 nmol)
i.c.v.
mice

Long lasting
analgesia
Block N/OFQ
effect on
locomotor
activity

[62]

(10 nmol)
i.t.
mice

Block N/OFQ
(i.t.1 nmol)
analgesic effect

[66]

(1–100 pmol)
i.c.v.
mice

Hyperalgesia
Decrease
locomotor
activity

[67]

(1–100 pmol)
i.t.
mice

Long lasting
dose
dependent
analgesia

[67]

(0.1 and
10 nmol/kg)
Intravenous (i.v.)
rats

Decrease heart
rate
Decrease blood
pressure
Decrease
urinary
sodium
excretion
Increase urine
flow

[67]

(1–10 nmol)
i.t.
monkey

Dosedependent
analgesia
without
inducing itch
Promotes
morphineinduced
analgesia
without
increasing itch
response

[68]
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Table 1. Cont.
In Vitro Human NOP Receptor
Name/Structure

Category

[Phe1Ψ (CH2 NH)Gly2 (pF)Phe4 Aib7 Arg14 Lys15 ]
N/OFQ-NH2
(UFP-113)

Selective NOP
receptor
partial agonist

Receptor
Binding
pKi

[35 S]GTPγS
pKB /pA2

10.26

9.72

7.97

PWT2-N/OFQ
Selective NOP
receptor
agonist

10.3

10.12

In Vivo

Ca+2
Administration
Mobilization Route/Dose/Species
pKB /pA2

8.83

Ref
Effect

(0.001–1 nmol)
i.t.
rats

Analgesia

[69]

(250 pmol)
i.c.v.
mice

Decease
locomotor
activity

[70]

(2.5–250 pmol)
i.t.
mice

Dosedependent
analgesia

[71]

(0.3, 1, and
3 nmol)
i.t.
monkey

Analgesia
No itching
No sedation
No
impairment in
motor activity

[71]

4.1.1. [Nphe1 ]N/OFQ(1-13)NH2
A preliminary hypothesis regarding the behavior of NOP receptor-active compounds
stated that if N/OFQ induces pain, antagonists are likely to exhibit antinociceptive activity.
To test this, [Nphe1 ]N/OFQ(1-13)-NH2 , the first reported peptide with antagonist activity,
was generated by shifting the side chain of Phe1 from C to N atom in the amidated N/OFQ.
A binding assay using Chinese hamster ovary (CHO) cells that express recombinant human
NOP receptor and cyclic AMP accumulation in CHO cells identified the antagonistic
properties of [Nphe1 ]N/OFQ(1-13)-NH2 . The mouse tail withdrawal assay revealed that
a single i.c.v. administration of [Nphe1 ]N/OFQ(1-13)NH2 increased the tail withdrawal
latency time, while a combinational administration of [Nphe1 ]N/OFQ(1-13)NH2 with
N/OFQ and morphine inverted the reduction of tail withdrawal latency time latency and
promoted the antinociceptive effect of morphine, respectively, implying the analgesic action
of this ligand [61,72].
4.1.2. [Nphe1 , Arg14 , Lys15 ]N/OFQ-NH2 (UFP-101)
Previous studies have shown that the binding of C-terminus-amidated N/OFQ to
the acidic restudies at the ECL2 of NOP receptor was enhanced by inserting Arg and
Lys [35,73]. Combination of [Nphe1 ]N/OFQ(1-13)-NH2 and [Arg14 , Lys15 ]N/OFQ-NH2
led to the generation of a new peptide [Nphe1 , Arg14 , Lys15 ]N/OFQ-NH2 , also called UFP101 [62]. In vitro assays including functional binding assays using (CHO cells expressing
human NOP receptor and [35 S]-GTPγS), cyclic AMP accumulation experiment, and Schild
regression analysis of electrically stimulated isolated peripheral (rats, mice, and guinea
pigs) and central tissues (rat) showed that UFP-101 competitively antagonized the effects
of N/OFQ. Similar to [Nphe1 ]N/OFQ(1-13)-NH2 , i.c.v. administration of 10 nmol UFP-101
produced antinociceptive effect in the mouse tail withdrawal assay, but with higher potency
and longer duration of action, indicating that the presence of Arg14 and Lys15 may promote
either the binding of UFP-101 to NOP receptor and/or the UFP-101 metabolic stability.
Since UFP-101 is a selective NOP receptor antagonist, it has been also used as a research tool
to confirm that NOP receptor mediates both the inhibition of spinal excitatory transmission
in vitro as well as the spinal antinociception in vivo [66].
4.1.3. [(pF)Phe4 Aib7 Arg14 Lys15 ]N/OFQ-NH2 (UFP-112)
The chemical modifications of the phenyl ring in Phe4 residue that is essential for
NOP receptor activation by inserting pF along with the replacement of Ala at position 7 by
α-aminoisobutyric acid (Aib) in N/OFQ sequence resulted in generation of more potent lig-
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ands [74–76]. By applying these two chemical modifications to [Arg14 , Lys15 ]N/OFQ-NH2 ,
[(pF)Phe4 Aib7 Arg14 Lys15 ]N/OFQ-NH2 , also known as (UFP-112), was synthesized [67].
This ligand acts as a potent (100-fold higher than N/OFQ) and a selective NOP receptor
agonist. A long-lasting dose dependent antinociceptive effect was observed after the i.t.
administration of UFP-112 (1–100 pmol) in the mouse tail withdrawal assay. In contrast,
the same dose of UFP-112 produced a pronociceptive effect and a long-lasting reduction in
the locomotor activity when it was administered intracerebroventricularly. Subsequent to
intravenous (i.v.) administration of UFP-112 in rats, diuresis as well as reduction in heart
rate, blood pressure, and urinary sodium excretion were significantly observed. Consistent
with the mouse tail withdrawal assay finding, a long-lasting dose dependent antinociceptive effect was also observed after the i.t. administration of UFP-112 (1–10 nmol) in
monkeys without inducing itching by using acute and chronic primate pain modalities
(acute noxious stimulus and capsaicin-induced thermal hyperalgesia, respectively) [68].
Notably, the spinal administration of a subthreshold dose of UFP-112 (1 nmol) synergized
a morphine analgesic effect without increasing pruritus.
4.1.4. [Phe1Ψ (CH2 -NH)Gly2 (pF)Phe4 Aib7 Arg14 Lys15 ]N/OFQ-NH2 (UFP-113)
The combination of [Phe1Ψ (CH2 -NH)Gly2 ](N/OFQ-NH2 that was synthesized to further
avoid the protease degradation [63] and the mentioned above [(pF)Phe4 Aib7 Arg14 Lys15 ]
N/OFQ-NH2, UFP-112, led to the generation of [Phe1Ψ (CH2 -NH)Gly2 (pF)Phe4 Aib7 Arg14
Lys15 ]N/OFQ-NH2 , also referred to as UFP-113 [77]. In vitro pharmacological characterization
studies that include the functional [35 S]-GTPγS binding in CHO cells that express the human
NOP receptor and electrically stimulated mouse and rat vas deferens and guinea pig ileum
tissues, reveals that UFP-113 acts as a selective partial agonist for NOP receptor [77]. The
spinal catheterization of UFP-113 induced an analgesic response in rats at doses that range
between (0.001 and 1 nmol); however, in the knockout of rats for the NOP receptor gene the
analgesic effect no longer persisted, implying that the antinociceptive effect of UFP-113 is
mediated through the NOP receptor stimulation [69].
4.1.5. PWT2-N/OFQ
By employing a novel chemical strategy using peptide wilding approach (PWT), three
tetrabranched derivatives of N/OFQ that include PWT1-N/OFQ, PWT2-N/OFQ, and
PWT3-N/OFQ were generated [78]. Both in vitro ([35 S]-GTPγS binding, calcium mobilization, and electrically stimulated mouse vas deferens assays) and in vivo studies using NOP
receptor gene knocked out [NOP receptor (−/−)], revealing that these PWT derivatives
act as full NOP receptor agonists that have high potency and a long duration of action
of, particularly in PWT2-N/OFQ (40-fold more potent than N/OFQ) [70]. Additionally,
analgesic effects were reported after the spinal administration of PWT2-N/OFQ using the
nociceptive pain model (tail withdrawal assay) and the neuropathic pain model (chronic
constriction injury) in mice and monkeys [71]. PWT2-N/OFQ exhibited higher potency
(40-fold more potent) and longer duration (10-fold longer duration of action) in comparison
to N/OFQ.
Despite having high potency and selectivity of the previously mentioned NOP receptor
peptides in targeting NOP receptor, their pharmacokinetic properties, specifically their poor
penetration across the blood-brain barrier have limited their therapeutic indications. However, these peptides have substantially contributed to the detailed understanding of the
various responses of the peripheral (respiratory, gastrointestinal, genitourinary, immune,
and cardiovascular systems) and central (pain transmission, anxiety, food intake, locomotion, and drug addiction) systems that are related to the N/OFQ–NOP receptor system.
4.2. Non-Peptide NOP Receptor Ligands Targeting Pain
To overcome the poor metabolic stability of peptide ligands related to N/OFQ and
require to be administered either intrathecally or intracerebroventricularly, several studies
were conducted to identify new selective non-peptide ligands that are suitable for in-
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traperitoneal or oral administration. High-throughput screening and medicinal chemistry
research have led to the discovery of multiple classes of chemical compounds including
piperidines, spiropiperidines, nortropanes, 4-amino-quinolines, and quinazolines that act
as NOP receptor ligands with enhanced metabolic stability. The non-peptides that have
antinociceptive activity are summarized in Table 2 and described below.
Table 2. Non-peptide NOP receptor ligands targeting pain.
In Vitro Human NOP Receptor
Name/Structure

Category

Receptor
Binding pKi

[35 S]GTPγS
pEC50

Ca+2
MobilizationpEC50

In Vivo

Ref

Administration
Route/Dose/Species

Effect

(0.1–1 mg/kg)
(0.03 to 1 µmol/kg)
i.v.
mice

Analgesia

[79,80]

(3 mg/kg)
(1 mg/kg)
intraperitoneal (i.p)
mice
(0.3 to 3 mg/kg)
i.p.
mice

Analgesia
Additive
analgesia
anxiolytic-like
effects

[81–83]

(0.001–0.06 mg/kg),
subcutaneous (s.c.)
monkey

Analgesia
No depression
No itching
No reinforcing

[17]

1–30 mg/kg)
peroral (p.o.)
rat

anxiolytic-like
effects

[84]

(0.1–3.0 mg/kg)
i.p., p.o.,
intracolonic
mice

potent antiinflammatory
and analgesic
effect

[85]

Ro 65-6570
NOP receptor
non
peptide agonist

8.6

Ro 64-6198
NOP receptor
nonpeptide
agonist

SCH221510

Selective NOP
receptor
nonpeptide
agonist

9.41

0.3

8.09

12

7.98

4.2.1. Ro 65-6570
The high-throughput screening of 8-acenaphthene-l-yl-l-phenyl-l,3,8-triaza-spiro[4.5]decan4-one was performed to develop Ro 65-6570, 8-(1,2-dihydroacenaphthylen-1-yl)-1-phenyl-1,3,8triazaspiro[4,5]decan-4-one, by a group of scientists at Roche laboratories [86]. In vitro studies
that include radioligand binding and cAMP inhibition assays in (CHO) cells expressing the
recombinant human NOP receptor indicated that Ro 65-6570 acts as a NOP receptor full agonist
with poor selectivity in comparison to other opioid receptors [87]. In mice, i.v. administration
of Ro 65-6570 resulted in dose-dependent antinociceptive effects without modifying motor
coordination using formalin paw and orofacial formalin (OFF) tests [79,80]. Further in vitro
functional selectivity studies such as the BRET-based assay revealed that Ro 65-6570 is a G
protein-biased agonist which exhibited antinociceptive effects in β-arrestin 2 knockout mice as
compared to the wild-type [88,89].
4.2.2. Ro 64-6198
In an effort to develop a new NOP receptor agonist with high selectivity (greater than
100-fold over canonical opioid receptors) and potency, [(1S,3aS)-8-(2,3,3a,4,5, 6- hexahydro1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza- spiro[4.5] decan-4-one], also known as Ro 64-6198,
was identified by a group of scientists at Hoffman La Roche in Switzerland [81,90,91].
Using Ro 64-6198 as a valuable pharmacological tool highlighted therapeutic applications for NOP receptor agonist such as anxiety, neuropathic pain, addiction, cough, and
anorexia, in addition to the undesirable effects it has on learning, memory, motor activity,
and body temperature (hypothermia) [92]. Similar to morphine, analgesic effects in the
hot plate and shock threshold assays were observed after the systemic administration of
Ro 64-6198 (3 mg/kg, intraperitoneal (i.p)) in wild-type mice but not in NOP receptor
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knockout mice [82,83]. Conversely, increased pain sensitivity was observed as an opposite
effect in the tail flick assay, implying the complex role of NOP receptor in pain processing. Furthermore, coadministration of low doses (1 mg/kg) of Ro 64-6198 and morphine
resulted in an additive analgesic effect [83]. Consistent with these findings, analgesic
effects without causing depression, itching, and reinforcing responses were observed after
the subcutaneous (s.c.) administration of Ro 64-6198 (0.001–0.06 mg/kg) in both acute
(acute noxious stimulus) and chronic (capsaicin-induced neuropathic pain) pain modalities
in monkeys [93]. Pretreatment with J-113397 (0.1 mg/kg), a selective nonpeptidic NOP
receptor antagonist, blocked Ro 64-6198-induced antinociception, emphasizing that the
antinociceptive actions of Ro 64-6198 is mediated via NOP receptor. Despite the robust
analgesic effects of systemically administered Ro 64-6198 in non-human primates, several
in vivo studies using tail flick and immersion, tactile or cold water stimulation and foot
shock assays revealed that Ro 64-6198 does not modulate pain processing in rodents, except
mouse hot plate assay [81,83,93–95].
4.2.3. SCH221510
SCH221510 is a potent and selective non-peptide NOP receptor agonist that was reported to induce analgesia in neuropathic pain when administered orally and intrathecally
in mice and rat models, respectively [96–98]. It is also reported to attenuate the respiratory depression and itch response that were observed after the systemic administration
of buprenorphine to a non-human primate, as well as reinforcing MOP receptor agonists
induced responses in rats [97,99]. Conversely, a s.c. administration of SCH221510 (3 and
10 mg/kg) in hot-plate test did not produce analgesia, while SCH221510 administration
(3 mg/kg) reduced morphine-induced analgesia. The co-administration of SCH221510
(3 mg/kg) and morphine (10 mg/kg) accelerated the tolerance development to the antinociceptive effect of morphine in female mice [100].
4.3. Bifunctional and Mixed NOP Receptor Compounds
Considering the potential ability of intracerebroventricularly administered N/OFQ to
attenuate morphine tolerance and suppress drug reinforcing response, the development
of new synthetic agonists may constitute an innovative pharmacological approach for
analgesics that target both MOP receptor and NOP receptor to enhance their analgesic
effect and minimize their side effects as depicted in Figure 2 [99,101–105]. Additionally,
multiple pathophysiological pathways are involved in the pain process, so developing
analgesic agents with multiple mechanisms of actions could be an innovative strategy
for developing new effective and safe analgesics [106]. Accordingly, several compounds
including AT-121 (a partial agonist of NOP receptor and MOP receptor), buprenorphine
(semisynthetic multifunctional opioid), and its analogue BU08028 were synthesized (reviewed in [107–109]).
4.3.1. SR 16435
SR 16435 (Figure 3), also referred to as [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4yl)indolin-2-one] behaved as a bi-functional NOP receptor /MOP receptor partial agonist
with high binding affinity was synthesized by Toll group [110]. In mice, SR 16435 administration produced an analgesic effect (s.c. and i.t.) which was effective and potent
in attenuating both neuropathic and inflammatory pain (i.t) with diminished tolerance
development to the antinociceptive effect of SR 16435 [96,110]. Nonetheless, the conditioned place preference (CPP) that was primarily mediated by MOP receptor activation was
induced after the administration of SR 16435. This finding emphasizes that full agonistic
activity at NOP receptor could be required to reduce the rewarding properties associated
with MOP receptor [110].
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Figure 2. Rational design of new safer analgesics. (A) Beneficiary and side effects produced by
MOP receptor activation. (B) Beneficiary (synergizing analgesic effect) and protective (ameliorating
typical-opioid side effect profile) effects produced by developing a new compound with simultaneous
agonistic activity at NOP receptor and MOP receptor.

Figure 3. Chemical structures and in vitro pharmacological profiles of bifunctional and mixed NOP
receptor ligands that target pain [99,110–119].
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4.3.2. AT-121
AT-121 (Figure 3) is a non- morphinan compound which acts as a bifunctional NOP
receptor /MOP receptor partial agonist with high binding affinity [114]. It was synthesized
to optimize the pharmacological profile of MOP receptor agonists by synergizing their
therapeutic effects (analgesia and treatment of substance abuse) and minimizing their side
effects (respiratory depression, tolerance dependent, and abuse liability) via targeting NOP
receptor. In monkeys, s.c. administration of AT-121 produced morphine-like analgesic and
antiallodynic effects using the warm water tail-withdrawal assay and capsaicin-induced
allodynia, respectively, without trigging itch, physical dependence, respiratory depression,
and hyperalgesia mediated by opioid. These effects were confirmed to be mediated by
MOP receptor and NOP receptor activation by using selective dose of MOP receptor and
NOP receptor antagonists, J-113397 (0.1 mg/kg) and naltrexone (0.03 mg/kg), respectively.
Additionally, AT-121 could be therapeutically implicated for opioid addiction as it lacks the
abuse potential (reinforcing effects) and diminished oxycodone reinforcing response.
4.3.3. Buprenorphine and Its Analog BU08028
Buprenorphine (Figure 3) is a natural derived alkaloid of the opium poppy with a
mixed pharmacological activity (MOP receptor /NOP receptor partial agonist and DOP
receptor /KOP receptor low partial agonist) clinically approved to treat pain and substance
abuse [99,115]. In rodent, full analgesic effects were produced after the administration of
buprenorphine in both chronic and acute pain models [120]. After a systemic administration
of 0.01–0.1 mg/kg to a non-human primate, an antinociceptive effect was present in a
dose-dependent manner. A resultant respiratory depression and itch were observed and
subsequently confirmed to be induced by MOP receptor activation. These side effects
associated with buprenorphine were found to be attenuated by the co-administration of
an NOP receptor selective agonist such as Ro 64-6198 and SCH 221510 [99]. As such,
the combination emphasized the therapeutic potential of mixed MOP receptor /NOP
receptor agonists as innovative analgesics. A buprenorphine analog that is known as
BU08028 (Figure 3) demonstrated a similar binding profile to buprenorphine with improved
binding affinity and efficacy to NOP receptor. In mice, an intrathecal administration of
BU08028 produced an analgesic effect, which was more potent than morphine in attenuating
both neuropathic and inflammatory pain [96]. Consistent with these results, a systemic
administration of BU08028 to a non-human primate produced a long-lasting analgesic
effect (>24 h) with a reduced reinforcing effect as compared to cocaine, remifentanil, or
buprenorphine and without causing respiratory depression and CVS adverse effects [121].
4.3.4. BPR1M97
By applying a high-throughput screening, BPR1M97 (Figure 3) was identified as a
dual agonist that produced a significant analgesic effect in a tail-flick assay in mice [122].
Both in vitro assays (radioligand binding, c-AMP production, membrane potential, βArrestin-2 recruitment, and internalization assays) and in vivo behavior assays (tail flick
and clip, respiratory and cardiovascular functional, acetone drop, von Frey hair, charcoal
meal, glass bead, locomotor activity, conditioned place preference (CPP) and naloxone
precipitation assays) proved that BPR1M97 behaved as a dual agonist for MOP receptor
(full agonist) and NOP receptor (G-protein biased agonist) [118]. Notably, rapid analgesic
actions (more potent than morphine in cancer-induced sensory allodynia) were observed
after the BPR1M97 s.c. administration with less undesirable side effect as compared
to morphine.
4.3.5. BU10038
A naltrexone-derived bifunctional MOP receptor /NOP receptor agonist, also referred
to as BU10038 (Figure 3), behaved as a partial MOP receptor and NOP receptor agonist
was synthesized by Husbands and Ko groups [117]. In non-human primate, both systemic (0.001–0.01 mg/kg) and intrathecal (3 mg) administrations of BU10038 resulted in a
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long-lasting antinociceptive with neither reinforcing effects nor other effects like itching,
respiratory depression, and tolerance when administered repeatedly.
4.3.6. JTC-801
JTC-801 (Figure 3), also referred to as [N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl) benzamide hydrochloride], behaved as a NOP receptor antagonist and was
developed by a group of scientists at the Central Pharmaceutical Research Institute [119].
JTC-801 produced antinociceptive effects in a hot plate test and a formalin test using
mice and rats, respectively. Although the injectable and oral formulations of JTC-801
entered Phase II of its clinical trials in both Japan and the UK to treat the neuropathic and
postoperative pain, it was suspended for unknown reasons [123].
4.3.7. Cebranopadol
The rational optimization strategy of spiro[cyclohexanedihydropyrano[3,4-b]indole]amine resulted in the discovery of cebranopadol (Figure 3) that represents the first in its class
to be a highly potent and efficacious antinociceptive agent with combined agonistic activity
at MOP receptor, NOP receptor (subnanomolar affinity), KOP receptor, and DOP receptor
(low nanomolar affinity) [111,112,124]. Behavior in vivo studies including acute and chronic
pain models in rodents (tail-flick, formalin test, rheumatoid arthritis, bone cancer, spinal
nerve ligation, diabetic neuropathy) further indicated the high potency and extremely
long-lasting analgesic effect of cebranopadol in comparison with selective MOP receptor
agonist, particularly in the chronic pain model [111,125]. Extensive preclinical safety and
tolerability studies have been conducted on rodent models to reveal the possible side effects
on the CNS, the respiratory system, and the gastrointestinal system (reviewed in [126]).
Limited range of unwanted effects were also observed, as cebranopadol did not decrease
respiratory rate, develop a tolerance, or impair the motor coordination, unlike the effects
of morphine. The G-protein-biased agonistic activity at NOP receptor could be the reason
behind these favorable side effect profiles of cebranopadol [125]. Notably, cebranopadol
is equipotent and equi-efficacious toward the G protein activation at both MOP receptor
and NOP receptor without inducing phosphorylation or NOP receptor internalization
and without recruiting B-arrestin2 at NOP receptor only in BRET assay [125,127]. The
noncompartmental analysis in phase I and phase II clinical trials was used to assess the
pharmacokinetics profiles of cebranopadol. The maximum plasma concentration [Cmax]
(4–6 h) with a long half-value duration (14–15 h) was reached after oral administration
of immediate release formulation of cebranopadol. After the administration of multiple
once-daily oral doses of cebranopadol in patients, the steady state was reached in nearly
2 weeks. Following single- and multiple-doses administration of cebranopadol in healthy
subjects and patients, a two-compartment disposition model with first-order elimination
process and a two lagged transition compartments was observed [128]. Several phase
II clinical trials were conducted and listed as complete in patients suffering from acute
(bunionectomy trial) and chronic (diabetic neuropathy, osteoarthritis, chronic low back
pain, and diabetic polyneuropathy) pain to evaluate the efficacy, safety, and tolerability of a
single oral dose of cebranopadol [129–135]. While most phase III clinical trials have recently
proven the effectiveness, safety, and tolerability of cebranopadol when administered orally
(200–1000 µg per day) to cancer patients who suffer from moderate to severe chronic
pain [136,137].
5. Future Directions and Conclusions
In this review, the rational design of NOP receptor ligands with various pharmacological profiles as a promising alternative for conventional opioid analgesic is discussed. The
crystal structure, distribution, and signaling pathway of NOP receptor are also highlighted.
It is important to note that other therapeutic indications for NOP receptor in the treatment
of various neurological disorders and alcohol abuse have not been explored in this review.
Notably, NOP receptor-related peptides have substantially attributed in expanding our
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knowledge regarding the various peripheral and central responses related to N/OFQ–NOP
receptor system, but their poor bioavailability has limited their therapeutic implications.
Regardless of the controversial results between the spinal and supraspinal administration
of endogenous neuropeptide of NOP receptor that remains poorly understood, the NOP
receptor ligands exhibit favorable pharmacological activity and side effects, particularly
the mixed which target multiple opioid receptors. So far, cebranopadol represents the
most promising NOP receptor ligand to treat acute and chronic pain without reducing
respiratory rate, developing a tolerance, or impairing the motor coordination as compared
to the clinically approved opioid analgesic. However, further work needs to be done
to resolve the high-resolution structure of NOP receptor in its active state to elucidate
the distinct residues responsible for NOP receptor agonist binding [138]. Conceivably,
a deep understanding of the NOP receptor signaling pathway and structure along with
computer-aided molecular docking and behavior studies will facilitate the discovery of
polypharmacological ligands that target multiple receptors including NOP receptor as new
effective and safe analgesics.
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